Heightened CD40 ligand gene expression in peripheral CD4+ T cells from patients with kidney allograft rejection

Transplantation. 2000 Aug 15;70(3):497-505. doi: 10.1097/00007890-200008150-00018.

Abstract

Background: CD40 ligand (CD40L) gene expression is increased in rejecting allograft biopsies. We, therefore, tested the possibility that CD40L gene expression is heightened in peripheral CD4+ T cells during renal allograft rejection.

Methods: CD40L gene expression in peripheral blood CD4+ T cells from two renal transplant groups was measured by quantitative reverse transcription-polymerase chain reaction (RT-PCR). Group 1: 20 patients with excellent renal transplant function; group 2: 25 patients with findings of acute and/or chronic allograft nephropathy (CAN); and group 3 of 12 normal controls. CD4+ cells were isolated by positive selection. The modifying effect of cyclosporine (CsA) and FK506 on CD40L gene expression was further tested in vitro in CD4+ T lymphocytes separated from pokeweed mitogen- (PWM) activated peripheral blood lymphocytes (PBL) preparations.

Results: Mean+/-SD expressions of CD40L gene, in aM, in groups 1-3 were as follows: 0.0052+/-0.0094; 0.022+/-0.023 (P=0.0038 vs. group 2); and 0.014+/-0.005. Levels of CD40L gene expression correlated significantly with acute rejection Banff 97 score (R2=0.44, P=0.0004) and severity of intertubular capillary changes (ITCC) (R2=0.33, P=0.011). After in vitro activation, CD40L gene expression increased by approximately 4-fold and the addition of CsA or FK506 diminished CD40L gene expression to a base level.

Conclusion: Peripheral CD4+ T cell CD40L gene expression increases significantly in acute rejection and CAN and may serve as a non-invasive method to monitor allograft function and determine the biological response to CsA and FK506.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Acute Disease
  • Adult
  • Base Sequence
  • CD4-Positive T-Lymphocytes / immunology*
  • CD40 Antigens / metabolism
  • CD40 Ligand
  • Case-Control Studies
  • Chronic Disease
  • Cyclosporine / therapeutic use
  • DNA Primers / genetics
  • Gene Expression / drug effects
  • Graft Rejection / drug therapy
  • Graft Rejection / genetics
  • Graft Rejection / immunology*
  • Humans
  • Immunosuppressive Agents / therapeutic use
  • In Vitro Techniques
  • Kidney Transplantation / adverse effects*
  • Kidney Transplantation / immunology*
  • Kidney Transplantation / pathology
  • Ligands
  • Membrane Glycoproteins / genetics*
  • Middle Aged
  • Tacrolimus / therapeutic use

Substances

  • CD40 Antigens
  • DNA Primers
  • Immunosuppressive Agents
  • Ligands
  • Membrane Glycoproteins
  • CD40 Ligand
  • Cyclosporine
  • Tacrolimus